Coya Therapeutics, Inc. (COYA)
NASDAQ: COYA · Real-Time Price · USD
4.650
-0.060 (-1.27%)
At close: Feb 17, 2026, 4:00 PM EST
4.560
-0.090 (-1.94%)
After-hours: Feb 17, 2026, 4:29 PM EST
Coya Therapeutics Employees
Coya Therapeutics had 8 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
8
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$498,463
Profits / Employee
-$2,304,168
Market Cap
109.03M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 8 | 0 | - |
| Dec 31, 2023 | 8 | 2 | 33.33% |
| Dec 31, 2022 | 6 | 0 | - |
| Sep 30, 2022 | 6 | 0 | - |
| Jun 30, 2022 | 6 | - | - |
| Dec 31, 2021 | 6 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| MacroGenics | 341 |
| Codexis | 188 |
| Inovio Pharmaceuticals | 134 |
| Seer, Inc. | 134 |
| Fortress Biotech | 101 |
| Immunic | 90 |
| Cardiff Oncology | 33 |
| Oncolytics Biotech | 28 |
COYA News
- 7 days ago - Coya Therapeutics to Host Webinar with Leading Medical Experts on Amyotrophic Lateral Sclerosis (ALS) Drug Development, Patient Landscape, and Ongoing Clinical Trial - Business Wire
- 18 days ago - Coya Therapeutics Announces $11.1 Million Private Placement - Business Wire
- 4 weeks ago - Coya Therapeutics CEO Dr. Arun Swaminathan Issues Letter to Stockholders - Business Wire
- 5 weeks ago - Coya Therapeutics Announces Results of Investigator-Initiated Study of LD IL-2 and CTLA4-Ig Demonstrating Treg Enhancement and Cognitive Stability in Frontotemporal Dementia Patients - Business Wire
- 6 weeks ago - Coya Therapeutics Announces U.S. FDA Acceptance of Investigational New Drug (IND) Application for COYA 302 for the Treatment of Frontotemporal Dementia (FTD) - Business Wire
- 2 months ago - Coya Therapeutics Receives Clinical Trial Application (CTA) Acceptance from Health Canada to Proceed with the COYA 302 ALSTARS Trial for the Treatment of Amyotrophic Lateral Sclerosis (ALS) - Business Wire
- 2 months ago - Coya Therapeutics Announces Patients Have Been Dosed in the ALSTARS Trial of COYA 302 for the Treatment of ALS - Business Wire
- 3 months ago - Coya Therapeutics to Participate in Upcoming Investor Relations and Clinical Trials Conferences - Business Wire